个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Wang, J.[1] * ; Duan, J.[2] ; Wu, L.[3] ; Wang, Q.[4] ; Xing, L.[5] ; Sun, Y.[5] ; Lu, P.[6] ; Ning, F.[7] ; Yang, H.[8,11,16] ; Su, H.[9] ; Yao, W.[10] ; Pan, P.[11] ; Yang, H.[8,11,16] ; Zhang, J.[12] ; Huang, J.[12] ; Chen, J.[3] ; Cheng, Y.[13] ; Li, Y.[14] ; Dong, X.[15] ; Shi, H.[16] ; Yang, H.[8,11,16] ; Zeng, A.[17] ; He, Z.[18] ; Pei, X.[19] ; Pang, P.[19] ; Sun, H.[20] ; Zhou, Y.[21] ; Zhang, M.[21] ; Dong, Y.[21] ;
机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing, Peoples R China [2]Shanxi Prov Canc Hosp, Taiyuan, Peoples R China [3]Hunan Canc Hosp, Changsha, Peoples R China [4]Henan Canc Hosp, Zhengzhou, Peoples R China [5]Shandong Canc Hosp, Jinan, Peoples R China [6]Xinxiang Med Univ, Affiliated Hosp 1, Weihui, Peoples R China [7]Binzhou Med Univ Hosp, Binzhou, Peoples R China [8]Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China [9]Air Force Mil Med Univ, Peoples Liberat Army China, Affiliated Hosp 2, Xian, Peoples R China [10]Sichuan Canc Hosp, Chengdu, Peoples R China [11]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China [12]Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China [13]Jilin Canc Hosp, Changchun, Peoples R China [14]Chongqing Univ Canc Hosp, Chongqing, Peoples R China [15]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China [16]Gannan Med Coll, Affiliated Hosp 1, Ganzhou, Peoples R China [17]Guangxi Med Uniwers Cenc Hosp, Nanning, Peoples R China [18]Fujian Canc Hosp, Fuzhou, Peoples R China [19]Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China [20]Jiamusi Canc Hosp, Jiamusi, Peoples R China [21]Shanghai Hansoh BioMed Co Ltd, Shanghai, Peoples R China
出处：
ISSN：

关键词： HS-20093 ES-SCLC ORR

摘要：
Introduction: ARTEMIS-001 study is a multicenter, open-label phase 1 study investigating the safety and efficacy of HS-20093 (GSK5764227), an antibody-drug conjugate targeting B7-H3, in advanced solid tumors (NCT05276609). Promising antitumor activity was observed across multiple tumor types, particularly in extensive stage small cell lung cancer (ES-SCLC) during the dose-escalation phase of the study (Jie Wang et al., JCO, 2023). Here, we present the latest efficacy and safety results of HS-20093 in ES-SCLC patients (pts) from both the doseescalation and dose-expansion phases.

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wang J.,Duan J.,Wu L.,et al.Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)[J].JOURNAL OF THORACIC ONCOLOGY.2024,19(10):S17-S17.
APA：
Wang, J.,Duan, J.,Wu, L.,Wang, Q.,Xing, L....&Dong, Y..(2024).Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001).JOURNAL OF THORACIC ONCOLOGY,19,(10)
MLA：
Wang, J.,et al."Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)".JOURNAL OF THORACIC ONCOLOGY 19..10(2024):S17-S17

相关文献

[1]注射用HS-20093的 I期临床研究 [2]HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors [3]ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors [4]Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial [5]注射用HS-20093 在晚期食管癌及其他晚期实体瘤患者中的临床研究 [6]ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) [7]注射用HS-20093 在广泛期小细胞肺癌患者中的期临床研究 [8]Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC) [9]注射用HS-20093对照主动监测用于局限期小细胞肺癌放化疗后巩固治疗的III期临床研究 [10]注射用HS-20093在头颈部鳞癌等实体瘤患者中的有效性和安全性的临床研究

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号